XtalPi, Viva-Thera nominate preclinical HIV-1 MPER drug candidate in seven months using AI platform

PUBT · 1d ago
XtalPi, Viva-Thera nominate preclinical HIV-1 MPER drug candidate in seven months using AI platform
  • XtalPi-backed Viva-Thera nominated a preclinical HIV-1 gp41 MPER candidate, completing discovery and optimization in seven months.
  • Program combined Viva-Thera’s atomic-resolution MPER-TMD-CT structure with XtalPi’s AI design platform, screening about 10 million compounds to five hits.
  • Asset targets gp41-mediated membrane fusion, positioning it as a potential broad-spectrum antiviral with a mechanism distinct from standard HIV drug classes.
  • Vaccine immunogens produced about 5x higher antibody levels in rhesus macaques versus a comparator, with antiviral activity retained at 1:1,000 dilution.
  • Gene-therapy work advanced a non-replicating HIV-derived CRISPR-Cas9 delivery vector, with mouse studies completed and live-virus studies planned.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xtalpi Holdings Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202609221336PR_NEWS_USPR_____CN54187) on September 22, 2026, and is solely responsible for the information contained therein.